HeartSciences (HSCS) Receivables - Net (2023 - 2025)
HeartSciences (HSCS) posted quarterly Receivables - Net of $4350.0 for Q4 2025, down 70.41% on a QoQ basis from $14700.0 in Q1 2024.
HeartSciences (HSCS) Receivables - Net (2023 - 2025) Analysis & Trends
HeartSciences (HSCS) has reported Receivables - Net for 3 consecutive years, with $4350.0 the latest figure, recorded in Q4 2025.
- Quarterly Receivables - Net changed N/A year-over-year to $4350.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4350.0 (changed N/A YoY) and the FY2025 annual result came in at $4350.0, changed N/A from the prior year.
- Receivables - Net fell to $4350.0 in Q4 2025 per HSCS's latest filing, from $14700.0 in the prior quarter.
- Over the last five years, Receivables - Net for HSCS reached as high as $14700.0 in Q1 2024 and fell as low as $3900.0 in Q4 2023.
- A 3-year average of $7650.0 and a median of $4350.0 in 2025 frame the typical range for Receivables - Net.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | HeartSciences | 2.29 Mn | -1.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4,350.00 |
| Dec 31, 2025 | 4,350.00 |
| Jan 31, 2024 | 14,700.00 |
| Jan 31, 2024 | 14,700.00 |
| Oct 31, 2023 | 3,900.00 |
| Oct 31, 2023 | 3,900.00 |